AIM - AIM ImmunoTech receives patent coverage in Netherlands for potential COVID-19 treatment

AIM ImmunoTech (NYSE:AIM) said on Monday the Netherlands Patent Office had issued a patent covering its drug Ampligen (rintatolimod) and other developed dsRNA products for use in the prevention or treatment of COVID-19. The base patent term extends until 2041. The company's drug Ampligen is RNA product candidate being developed for cancers, viral diseases and disorders of the immune system. (AIM) expects to file an Investigational New Drug application with the U.S. FDA for a Phase 2 study of Ampligen to treat Post-COVID conditions.

For further details see:

AIM ImmunoTech receives patent coverage in Netherlands for potential COVID-19 treatment